TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16136769
Drug: Fluticasone propionate-salmeterol
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate-salmeterol (100/50 microg, twice daily)
Study: 16136769
Drug: Montelukast (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (once daily)
Study: 12351465
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g daily for 8 weeks)
Study: 30387859
Drug: Chewed Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed Oxycodone DETERx fasted
Study: 30387859
Drug: Intact Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact Oxycodone DETERx fasted
Study: 30387859
Drug: Intact Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact Oxycodone DETERx fed
Study: 21309477
Drug: Semi-closed circuit
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-closed circuit anaesthesia (SCA) 4 l/min
Study: 16244028
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine with 1.4% NaHCO3 (group small dose)
Study: 7607749
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatments (including sucrose gum)
Study: 2230911
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g i.v.) at the time of anesthesia
Study: 31702486
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg twice daily for 4 days followed by metoclopramide 20 mg
Study: 26237354
Drug: Inhaled Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Interferon gamma (IFN‐γ) for 80 weeks
Study: 31119846
Drug: TRK‐100STP 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRK‐100STP 240 μg
Study: 17115157
Drug: AZD5438 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5438 80 mg
Study: 17115157
Drug: AZD5438 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5438 160 mg
Study: 17115157
Drug: AZD5438 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5438 (various doses)
Study: 8094111
Drug: Active taper
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active taper
Study: 29247782
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 1000 IU of vitamin D and 500 mg of calcium for six months
Study: 29247782
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 1000 IU of vitamin D and 500 mg of calcium
Study: 26712558
Drug: Aminophylline (theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (theophylline salt formulation)
Study: 10208192
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (42 microg twice daily)
Study: 10208192
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (36 microg four times a day)
Study: 10208192
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (2 puffs four times a day)
Study: 7788426
Drug: Oral atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atovaquone for mild to moderate PCP
Study: 7788426
Drug: Oral atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral atovaquone for severe PCP
Study: 9742976
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (overall)
Study: 8048498
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) + Spironolactone (Spi) (200 mg)
Study: 8048498
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) + Mifepristone (Mif) (400 mg)
Study: 1101838
Drug: Spironolactone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (300 to 450 mg daily)
Study: 19837005
Drug: Spinal Manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulative Therapy (SMT)
Study: 21300181
Drug: Replication‐Competent Adenovirus‐mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replication‐Competent Adenovirus‐mediated Suicide Gene Therapy followed by radiation (Arm 1)
Study: 17886708
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and radiotherapy
Study: 2440632
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg three times a day)
Study: 29127949
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus intravitreous dexamethasone implant (700 μg)
Study: 29127949
Drug: Ranibizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.3 mg) alone
Study: 26091907
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (methotrexate+golimumab)
Study: 24168956
Drug: Methotrexate-monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate-monotherapy
Study: 25172879
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (daily motivational messages about nutrition and physical activity)
Study: 10447578
Drug: Nolatrexed 725
Normalized name: Nolatrexed
DrugBank: Nolatrexed (DB12912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolatrexed 725 mg/m(2)/day by continuous infusion for 5 days
Study: 10447578
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m(2) as rapid intravenous infusion every 3 weeks
Study: 7783102
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (7.1 pM/kg per min) during euglycemic hyperinsulinaemic glucose clamp
Study: 7783102
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin concentrations
Study: 569995
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg IV
Study: 27324337
Drug: non-opioid/opioid analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-opioid/opioid analgesic combinations plus topical 0.25% bupivacaine onto the cystic plate and local 0.25% bupivacaine port-site injection
Study: 26445140
Drug: Mepolizumab 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 75 mg IV
Study: 26445140
Drug: Mepolizumab SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab SC doses providing 50% inhibition
Study: 11742962
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily T‐piece weaning or pressure support
Study: 29673465
Drug: Ibuprofen with
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen with aspirin
Study: 20799399
Drug: Immunovac‐VP4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunovac‐VP4 vaccine
Study: 18388929
Drug: NV1FGF (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV1FGF (2.5 ml at 0.2 mg/ml, 8 intramuscular injections on days 1, 15, 30, and 45)
Study: 10727077
Drug: Vitamin antioxidant
Normalized name: Glucosamine/Chondroitin Sulfate A/Multivitamin Antioxidant 5 400 mg-300 mg-425 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin antioxidant mixture (600 mg alpha‐tocopherol, 1,000 mg vitamin C, 32 mg beta‐carotene)
Study: 1510435
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ceftazidime (1-g dose)
Study: 1510435
Drug: Endotracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal administration of ceftazidime (1-g dose)
Study: 1510435
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of ceftazidime (1-g dose)
Study: 20197487
Drug: 350 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg, 700 mg, 1400 mg, or 2100 mg of artemisinin-naphthoquine phosphate
Study: 20197487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of artemisinin and naphthoquine phosphate
Study: 20197487
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose administration
Study: 17905357
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken twice daily for 12 weeks
Study: 11905547
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide 200 microg metered dose inhaler (MDI) administered by Fluspacer
Study: 2146282
Drug: DHEA (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (1600 mg/day, orally)
Study: 31757
Drug: Morphine anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine anaesthesia (4 mg/kg before skin incision)
Study: 31499206
Drug: Single-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rifampicin (SDR) after BCG vaccination
Study: 20101064
Drug: efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz 600 mg intact capsules under fasting conditions
Study: 10099127
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization
Study: 23671895
Drug: Amitriptyline 10mg
Normalized name: amitriptyline 10 MG
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline 10mg daily
Study: 23671895
Drug: Amitriptyline 10mg
Normalized name: amitriptyline 10 MG
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline 10mg daily with Pindolol 5mg twice daily
Study: 23671895
Drug: Surrogate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrogate placebo (Loratadine 10mg daily)
Study: 17353873
Drug: New compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: New compounds targeting androgen receptors
Study: 10383560
Drug: Oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetazoline nasal spray (0.9 mg)
Study: 12074329
Drug: FHIG (infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHIG (infusional fluorouracil 2.6 g/m2 over 24 hours once per week for 6 weeks, infusional hydroxyurea 4.3 g/m2 over 24 hours once per week for 6 weeks, interferon-alpha-2a 9 MU subcutaneously three times per week for 6 weeks)
Study: 12074329
Drug: AD (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 intravenously every 21 days)
Study: 8961505
Drug: rhGM-CSF (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF (20-40 micrograms, injected at the same site as the vaccine)
Study: 29696357
Drug: Post-acute assessment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-acute assessment (8 weeks after first in-patient treatment)
Study: 17556408
Drug: TAK-044 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 (100 mg)
Study: 14736774
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of latanoprost 0.005% and timolol 0.5% (once daily morning dose)
Study: 14736774
Drug: Unfixed combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfixed combination of latanoprost 0.005% (once daily evening) and timolol 0.5% (twice daily)
Study: 11910258
Drug: Fluoxetine, Sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, Sertraline, Paroxetine
Study: 1388702
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml NaCl)
Study: 26485501
Drug: Complete device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete device removal and antibiotic treatment for six weeks
Study: 11942883
Drug: Hydralazine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (5-10 mg intravenous)
Study: 132705
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline preparation
Study: 132705
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline 0.5 gm daily
Study: 15696244
Drug: Edifoligide (E2F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edifoligide (E2F Decoy) administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation.
Study: 10547465
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus radiation
Study: 31596491
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (systolic blood pressure target < 120 mm Hg)
Study: 31596491
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure target < 140 mm Hg)
Study: 24637999
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (C2 to C22)
Study: 24637999
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (C2 to C6) plus placebo (C7 to C22)
Study: 24637999
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus placebo (C2 to C22)
Study: 17627173
Drug: IM injection
Normalized name: filgrastim Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of 40 mg piroxicam
Study: 17627173
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg piroxicam FDDF sublingual tablets
Study: 22220766
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg followed by 250 mg 24 hours later
Study: 15040643
Drug: Zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 600 mg once/day
Study: 8002329
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of sublingual apomorphine
Study: 7802151
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (AP): alfentanil 30 micrograms/kg and propofol 1.5 mg/kg
Study: 7802151
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (SE): sufentanil 0.3 microgram/kg and etomidate 0.3 mg/kg
Study: 7802151
Drug: Group IV
Normalized name: Corticosteroids, very potent (group IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IV (SP): sufentanil 0.3 microgram/kg and propofol 1.5 mg/kg
Study: 28486629
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with ropivacaine 0.15%, 1.5 ml kg ‐1 (High-Volume group)
Study: 28486629
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with ropivacaine 0.15%, 1.0 ml kg ‐1 (Low-Volume group)
Study: 26419732
Drug: Anticholinergic medication
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic medication exposure
Study: 21160054
Drug: Applied behaviour
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied behaviour analysis by a specialist team plus standard treatment
Study: 11308049
Drug: rhGH (Genotropin)
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (Genotropin) at a dose of 0.2 IU/kg/day as daily s.c. injections for two years
Study: 7950213
Drug: Single-blind treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blind treatment with EF
Study: 31229401
Drug: Deferasirox and
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox and deferoxamine combination (30 mg/kg deferasirox daily plus SC 50 mg/kg deferoxamine for 5 days a week)
Study: 25405276
Drug: Fentanyl (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (200 μg before ERCP)
Study: 25405276
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal placebo before ERCP and placebo during ERCP)
Study: 23234763
Drug: Lapatinib (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1500 mg daily for 12 months)
Study: 12091295
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (100 microg four times daily for 10 days via Aerochamber)
Study: 20705782
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of lidocaine 2% 30 mL
Study: 20705782
Drug: Triple injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple injection adjacent to each brachial plexus cord
Study: 16255952
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of NPPV plus standard medical treatment (group B)
Study: 10088941
Drug: Oxaceprol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaceprol (200 mg three times daily)
Study: 10088941
Drug: Diclofenac (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (25 mg three times daily)
Study: 7562088
Drug: Alcohol treatment
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatment (30 g/d)
Study: 7562088
Drug: No alcohol
Normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alcohol treatment (energy replaced with carbohydrate)
Study: 1705137
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg three times daily)
Study: 1705137
Drug: Toloxatone (400-200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toloxatone (400-200-400 mg day-1)
Study: 6450544
Drug: Oxygen/nitrous oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen/nitrous oxide sedation (relative analgesia) with diazepam premedication 0.2 mg/kg
Study: 31134784
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy training for 8 weeks, 16 sessions, combined with conventional therapy 5 days a week
Study: 23165381
Drug: Intranasal theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal theophylline methylpropyl paraben, 20 μg/d in each naris for 4 weeks
Study: 17437343
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral calcium and vitamin D supplementation starting on postoperative day 1
Study: 17437343
Drug: No routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No routine oral calcium and vitamin D supplementation
Study: 11865132
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (9-30 mg; mean dosage 16 mg)
Study: 1377036
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (total greater than 5 x 10(6) kallikrein inactivator units [KIU])
Study: 1377036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no aprotinin administration)
Study: 6714602
Drug: New solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: New solution containing mainly sodium sulfate and polyethylene glycol (solution II)
Study: 6714602
Drug: Balanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced standard electrolyte solution (solution I)
Study: 31375087
Drug: Rituximab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (two 375 mg/m2 doses, maximum dose: 500 mg)
Study: 29468764
Drug: Hesperidin 500
Normalized name: Ascorbic Acid/Bioflavonoid/Hesperidin 500 MG-100 MG-100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hesperidin 500 mg/day
Study: 19854713
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral DHEA
Study: 10948809
Drug: Antihistamine nasal
Normalized name: Antihistamine Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine nasal spray (azelastine hydrochloride)
Study: 3542982
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of fluphenazine hydrochloride
Study: 29504794
Drug: Emotion Regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion Regulation Therapy (ERT)
Study: 24385117
Drug: luliconazole cream
Normalized name: Luliconazole Cream
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: luliconazole cream 1%
Study: 15189367
Drug: Alfacalcidol 0.25
Normalized name: alfacalcidol 0.25 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Study: 7658310
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 300 U/kg rhEPO in healthy non-pregnant volunteers
Study: 2487544
Drug: naloxone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (0.2 mg/kg) infusion
Study: 22120829
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infusion
Study: 30445841
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (losartan plus lisinopril)